secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-209044
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M
----------------------------------------------------------------------------

- Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
- Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.
- Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.
- Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.
- NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/0001193125-26-209044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/d54063d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-209044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer